Sompo Asset Management Co. Ltd. Has $910,000 Holdings in Zoetis Inc. (NYSE:ZTS)

Sompo Asset Management Co. Ltd. lessened its stake in Zoetis Inc. (NYSE:ZTS) by 2.4% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,250 shares of the company’s stock after selling 130 shares during the quarter. Sompo Asset Management Co. Ltd.’s holdings in Zoetis were worth $910,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Aveo Capital Partners LLC acquired a new position in Zoetis during the fourth quarter worth about $225,000. Gryphon Financial Partners LLC raised its stake in Zoetis by 11.8% during the fourth quarter. Gryphon Financial Partners LLC now owns 3,056 shares of the company’s stock worth $601,000 after acquiring an additional 322 shares in the last quarter. Jump Financial LLC acquired a new position in Zoetis during the fourth quarter worth about $339,000. TrinityPoint Wealth LLC raised its stake in Zoetis by 0.3% during the fourth quarter. TrinityPoint Wealth LLC now owns 22,319 shares of the company’s stock worth $4,405,000 after acquiring an additional 73 shares in the last quarter. Finally, Franklin Resources Inc. raised its stake in Zoetis by 8.9% during the fourth quarter. Franklin Resources Inc. now owns 161,489 shares of the company’s stock worth $31,873,000 after acquiring an additional 13,236 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. BTIG Research upped their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Piper Sandler upped their price objective on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Argus raised Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Finally, Stifel Nicolaus upped their price objective on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Zoetis currently has an average rating of “Buy” and a consensus target price of $220.38.

Zoetis Stock Down 0.3 %

ZTS stock opened at $192.73 on Friday. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. The company has a market capitalization of $87.94 billion, a price-to-earnings ratio of 37.13, a PEG ratio of 2.98 and a beta of 0.88. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The stock has a fifty day moving average of $184.70 and a 200-day moving average of $174.47.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, topping the consensus estimate of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The business had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. During the same quarter last year, the company earned $1.41 EPS. The firm’s revenue was up 8.3% compared to the same quarter last year. As a group, equities research analysts predict that Zoetis Inc. will post 5.84 earnings per share for the current year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.